Molecular Forecaster and TransBIOTech Partner to Accelerate the Discovery of New Small Therapeutic Molecules
MONTREAL AND LÉVIS, CANADA, JUNE 16, 2025 – Molecular Forecaster Inc. (MFI) and TransBIOTech are pleased to announce a strategic partnership that leverages the complementary strengths of both organizations to develop drug discovery programs combining MFI's customized computer-aided drug design (CADD) solutions with TransBIOTech's in vitro and in vivo expertise.
MFI and TransBIOTech share a common mission to accelerate the design and preclinical development phases of drugs. MFI is a research-as-a-service (RaaS – research-as-a-service) organization that combines human expertise with proprietary technology to integrate chemistry and computational modeling, thereby reducing design cycles in small molecule campaigns. TransBIOTech is a college research center affiliated with Cégep de Lévis. The organization offers cutting-edge expertise in cellular and molecular biology, pharmacology, and analytical chemistry to accelerate the progression of new therapeutic candidate molecules towards clinical trials through tailored preclinical efficacy and safety studies.
This partnership strengthens the synergies between computational and preclinical research, thereby facilitating the transition from in silico prediction to in vitro and in vivo validation. Through this collaboration, TransBIOTech is now able to offer integrated computer-aided design solutions, combining MFI's in silico predictions with tailored experimental validation. MFI's clients and partners will benefit from direct access to preclinical research laboratories and expertise in candidate optimization, enabling rapid validation and risk reduction prior to GLP (Good Laboratory Practice) certification.
"It is crucial, at this moment, to strengthen life sciences ecosystems in Quebec, Canada, and other jurisdictions worldwide," states Joshua Pottel, Founder and CEO of Molecular Forecaster. "At MFI, we choose to collaborate with organizations that create opportunities for our clients and the market. Our relationship with TransBIOTech establishes a strong bridge between computational and experimental expertise, enabling our clients to connect computational modeling results with concrete experimental data, swiftly and efficiently."
"By partnering with Molecular Forecaster, we strengthen our support for companies developing new drug candidates," adds Delphine Davan, Head of Partnerships and Business Development at TransBIOTech. "This strategic collaboration will enable us to offer a complete and integrated chain of expertise, ranging from molecular modeling to preclinical validation."
– 30 –
About Molecular Forecaster Inc.
Molecular Forecaster Inc. (MFI) helps companies make smarter decisions in drug design. For six years, we have been democratizing computer-aided drug design through our highly collaborative research-as-a-service model. Today, we are integrating what we have learned into new and improved software tools. Our goal? To become the go-to partner for small molecule drug design, combining proprietary tools and technologies, our expertise and know-how, and our comprehensive collaborative approach that sets our partners on the path to success.
Contact: Josh Pottel, CEO
About TransBIOTech
TransBIOTech, a College Technology Transfer Center (CCTT) affiliated with Cégep de Lévis, QC, Canada, is a research center and a non-profit organization specializing in biotechnology. Since 1999, TransBIOTech has offered expert support in drug development, providing tailored services in pharmacology, cellular and molecular biology, biochemistry, pharmacokinetics, and toxicology. TransBIOTech researchers utilize their expertise and advanced methodologies to evaluate the mechanism of action, efficacy, and safety of therapeutic molecules at various stages of preclinical development.
Contact: Delphine Davan, Head of Partnerships and Business Development
